JP2012244993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012244993A5 JP2012244993A5 JP2012119327A JP2012119327A JP2012244993A5 JP 2012244993 A5 JP2012244993 A5 JP 2012244993A5 JP 2012119327 A JP2012119327 A JP 2012119327A JP 2012119327 A JP2012119327 A JP 2012119327A JP 2012244993 A5 JP2012244993 A5 JP 2012244993A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- daclizumab
- dac hyp
- administered
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490998P | 2011-05-27 | 2011-05-27 | |
| US61/490,998 | 2011-05-27 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016161679A Division JP2016210796A (ja) | 2011-05-27 | 2016-08-22 | Ｄａｃ ｈｙｐ組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012244993A JP2012244993A (ja) | 2012-12-13 |
| JP2012244993A5 true JP2012244993A5 (https=) | 2015-04-09 |
| JP6055615B2 JP6055615B2 (ja) | 2016-12-27 |
Family
ID=46177353
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012119327A Expired - Fee Related JP6055615B2 (ja) | 2011-05-27 | 2012-05-25 | Ｄａｃｈｙｐ組成物および方法 |
| JP2016161679A Pending JP2016210796A (ja) | 2011-05-27 | 2016-08-22 | Ｄａｃ ｈｙｐ組成物および方法 |
| JP2018073025A Pending JP2018134091A (ja) | 2011-05-27 | 2018-04-05 | Ｄａｃ ｈｙｐ組成物および方法 |
| JP2020034673A Withdrawn JP2020078348A (ja) | 2011-05-27 | 2020-03-02 | Ｄａｃ ｈｙｐ組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016161679A Pending JP2016210796A (ja) | 2011-05-27 | 2016-08-22 | Ｄａｃ ｈｙｐ組成物および方法 |
| JP2018073025A Pending JP2018134091A (ja) | 2011-05-27 | 2018-04-05 | Ｄａｃ ｈｙｐ組成物および方法 |
| JP2020034673A Withdrawn JP2020078348A (ja) | 2011-05-27 | 2020-03-02 | Ｄａｃ ｈｙｐ組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US20120301429A1 (https=) |
| EP (1) | EP2527429A3 (https=) |
| JP (4) | JP6055615B2 (https=) |
| CN (2) | CN107090040A (https=) |
| AU (4) | AU2012203095B2 (https=) |
| BR (1) | BR102012012673A8 (https=) |
| CA (1) | CA2777978A1 (https=) |
| MX (1) | MX339533B (https=) |
| RU (2) | RU2661764C2 (https=) |
| SG (1) | SG185920A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6055615B2 (ja) | 2011-05-27 | 2016-12-27 | アッヴィ バイオテクノロジー リミテッド | Ｄａｃｈｙｐ組成物および方法 |
| CA2844662A1 (en) | 2011-08-08 | 2013-02-14 | Abbvie Biotherapeutics Inc. | Methods of treating progressive forms of multiple sclerosis |
| US20140295497A1 (en) * | 2011-11-30 | 2014-10-02 | Taymar E. Hartman | Vectors and host cells comprising a modified sv40 promoter for protein expression |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| CN105518020A (zh) | 2013-09-04 | 2016-04-20 | Emd密理博公司 | 清洗基于a蛋白的亲和色谱柱的方法 |
| GB201503578D0 (en) * | 2015-03-03 | 2015-04-15 | Ge Healthcare Bio Sciences Ab | Sanitization method for affinity chromatography matrices |
| JP7133925B2 (ja) * | 2015-03-23 | 2022-09-09 | アレクシオン ファーマシューティカルズ インコーポレイテッド | ウイルス濾過 |
| RU2021101009A (ru) | 2015-08-12 | 2021-02-20 | Пфайзер Инк. | Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| JP6937309B2 (ja) | 2016-01-27 | 2021-09-22 | ジャスト−エヴォテック バイオロジックス、インコーポレイテッド | ハイブリッドプロモーターおよびその使用 |
| WO2018027195A1 (en) * | 2016-08-05 | 2018-02-08 | Abbvie Biotherapeutics Inc. | Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same |
| AU2018212974B2 (en) * | 2017-01-30 | 2023-08-24 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for reducing bioburden in chromatography |
| KR102753090B1 (ko) * | 2017-12-21 | 2025-01-14 | 젠자임 코포레이션 | 단백질 a 크로마토그래피 동안 불순물의 향상된 제거를 위한 방법 |
| WO2020214792A1 (en) * | 2019-04-17 | 2020-10-22 | Bristol-Myers Squibb Company | Methods for regenerating chromatography resins |
| KR102731889B1 (ko) * | 2019-07-18 | 2024-11-19 | 에이비온 주식회사 | 2당화된 인터페론-베타 단백질의 정제 방법 |
| CA3146209A1 (en) * | 2019-08-01 | 2021-02-04 | John MATTILA | Method for viral inactivation |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| JP7631742B2 (ja) * | 2020-11-10 | 2025-02-19 | 東ソー株式会社 | ペプチド性リガンド固定化カラムの洗浄方法 |
| EP4334356A1 (en) * | 2021-05-03 | 2024-03-13 | Boehringer Ingelheim International Gmbh | Method for producing spesolimab |
| CN114181300A (zh) * | 2021-12-20 | 2022-03-15 | 方坦思(上海)生物医药有限公司 | 一种高纯度单克隆抗体的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1430566A (en) * | 1974-11-15 | 1976-03-31 | Nestel Sa | Isolation of proteins |
| US7442777B2 (en) * | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| RU2318537C2 (ru) * | 2001-04-06 | 2008-03-10 | Юниверсити Оф Бристоль | Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам |
| JP2005325133A (ja) * | 2001-10-15 | 2005-11-24 | Kirin Brewery Co Ltd | 抗ｈｌａ−ｄｒ抗体の利用 |
| US20040002135A1 (en) * | 2002-03-28 | 2004-01-01 | Sauer Paul W. | Adapted NS0 cell lines with the ability to grow under glutamine-free conditions |
| US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JPWO2004087761A1 (ja) * | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| WO2007146847A2 (en) | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| JP2010510963A (ja) * | 2006-06-14 | 2010-04-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | セラミックヒドロキシアパタイトを使用する抗体の精製方法 |
| WO2008004931A1 (en) * | 2006-07-06 | 2008-01-10 | Ge Healthcare Bio-Sciences Ab | Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol |
| JP2011512875A (ja) * | 2008-03-11 | 2011-04-28 | ジェネンテック， インコーポレイテッド | 増強されたａｄｃｃ機能を有する抗体 |
| RU2011111391A (ru) * | 2008-08-28 | 2012-10-10 | Эбботт Байотерапьютикс Корп. (Us) | Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r |
| US20120329709A1 (en) * | 2009-05-26 | 2012-12-27 | Brian Edward Collins | Production of glycoproteins |
| CA2763164A1 (en) | 2009-06-05 | 2010-12-09 | Momenta Pharmaceuticals, Inc. | Methods of modulating fucosylation of glycoproteins |
| EP2462157B1 (en) * | 2009-08-07 | 2020-06-17 | EMD Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
| US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
| US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| JP6055615B2 (ja) * | 2011-05-27 | 2016-12-27 | アッヴィ バイオテクノロジー リミテッド | Ｄａｃｈｙｐ組成物および方法 |
-
2012
- 2012-05-25 JP JP2012119327A patent/JP6055615B2/ja not_active Expired - Fee Related
- 2012-05-25 CN CN201710204584.8A patent/CN107090040A/zh active Pending
- 2012-05-25 RU RU2012121876A patent/RU2661764C2/ru active
- 2012-05-25 MX MX2012006115A patent/MX339533B/es active IP Right Grant
- 2012-05-25 BR BR102012012673A patent/BR102012012673A8/pt not_active Application Discontinuation
- 2012-05-25 CA CA2777978A patent/CA2777978A1/en not_active Abandoned
- 2012-05-25 SG SG2012038774A patent/SG185920A1/en unknown
- 2012-05-25 AU AU2012203095A patent/AU2012203095B2/en not_active Ceased
- 2012-05-25 US US13/481,081 patent/US20120301429A1/en not_active Abandoned
- 2012-05-25 EP EP12169595.1A patent/EP2527429A3/en not_active Withdrawn
- 2012-05-25 CN CN2012102472614A patent/CN102796705A/zh active Pending
- 2012-05-25 RU RU2018119112A patent/RU2018119112A/ru not_active Application Discontinuation
-
2015
- 2015-01-21 US US14/601,909 patent/US9676860B2/en not_active Expired - Fee Related
- 2015-03-27 US US14/671,653 patent/US9340619B2/en not_active Expired - Fee Related
- 2015-06-09 US US14/735,062 patent/US9260528B2/en not_active Expired - Fee Related
-
2016
- 2016-05-04 AU AU2016202873A patent/AU2016202873B2/en not_active Ceased
- 2016-08-22 JP JP2016161679A patent/JP2016210796A/ja active Pending
-
2017
- 2017-05-04 US US15/587,127 patent/US9815903B2/en not_active Expired - Fee Related
- 2017-10-04 US US15/724,443 patent/US20180127506A1/en not_active Abandoned
-
2018
- 2018-01-29 AU AU2018200654A patent/AU2018200654A1/en not_active Abandoned
- 2018-04-05 JP JP2018073025A patent/JP2018134091A/ja active Pending
-
2020
- 2020-01-31 US US16/779,336 patent/US20200157230A1/en not_active Abandoned
- 2020-03-02 JP JP2020034673A patent/JP2020078348A/ja not_active Withdrawn
- 2020-03-31 AU AU2020202298A patent/AU2020202298A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012244993A5 (https=) | ||
| RU2018119112A (ru) | Композиции и способы на основе dac hyp | |
| EP2964674B1 (en) | Anti-tnf-anti-il-17 bispecific antibodies | |
| TW516962B (en) | A human TNFR1-IgG1 preparation | |
| US20080167450A1 (en) | Methods of purifying proteins | |
| KR20120100914A (ko) | 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료 | |
| AU2017206006B2 (en) | Modulation of afucosylated species in a monoclonal antibody composition | |
| MX2014000093A (es) | Composiciones del polipéptido de fusión tnfr: fc exentas de argina y métodos de uso. | |
| JP6514789B2 (ja) | 新規組換え抗ＴＮＦ−αキメラモノクローナル抗体の製造方法及び用途 | |
| WO2013166099A1 (en) | Novel antibodies | |
| US20190048070A1 (en) | Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition | |
| EP3101035A1 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
| CN107208081B (zh) | 用于从包含污染宿主细胞蛋白质的材料纯化重组人α-半乳糖苷酶A的方法 | |
| WO2017038986A1 (ja) | 組換えタンパク質の製造方法 | |
| TWI891671B (zh) | 血清白蛋白與生長激素之融合蛋白質之製造方法 | |
| HK40091815A (zh) | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 | |
| HK40091814A (zh) | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 | |
| HK1241916A1 (en) | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |